deferoxamine has been researched along with thiazoles in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (23.08) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, E; Jacobs, A; Peter, H; Wong, A | 1 |
| Cook, EP; Fragonas, JC; Hunt, NH | 1 |
| Bergeron, RJ; Evans, KM; Jenny, HB; Luchetta, G; Peter, H; Streiff, RR; Vinson, JR; Wiegand, J | 1 |
| Bierer, BE; Nathan, DG | 1 |
| Chaudhri, G; Clark, IA | 1 |
| Finger, J; Hegsted, M; Nathan, DG; Nicolosi, RJ; Peter, H; Renaud, MM; Wolfe, LC | 1 |
| Baquet, A; Crichton, RR; Florence, A; Jin, Y; Schneider, YJ | 1 |
| Beaudoin, RL; Gentilini, M; Guillouzo, A; Landau, I; Langlois, P; Mazier, D; Mellouk, S; Miltgen, F; Stahel, E | 1 |
| Fritsch, G; Jung, A; Sawatzki, G; Spira, DT; Treumer, J | 1 |
| Crichton, RR; Longueville, A | 1 |
| Friedman, H; Gebran, SJ; Klein, TW; Newton, CA; Yamamoto, Y | 1 |
| Bergeron, RJ; Creary, EA; Daniels, RD; King, W; Luchetta, G; Moerker, T; Peter, HH; Streiff, RR; Wiegand, J | 1 |
| Bergeron, RJ; Ratliff-Thompson, K; Weimar, WR; Wiegand, J | 1 |
| Ewing, MM; Philbert, MA; Tjalkens, RB | 1 |
| Baker, E; Chua, AC; Kicic, A | 1 |
| Dirnagl, U; Isaev, N; Karsch, M; Megow, D; Meisel, A; Prass, K; Priller, J; Ruscher, K; Scharff, A | 1 |
| Drago, D; Filippi, B; Ricchelli, F; Tognon, G; Zatta, P | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Kontoghiorghes, GJ | 2 |
| Kowdley, KV; Messner, DJ; Sivam, G | 1 |
| Gaboriau, F; Lescoat, G; Mislin, GL; Rivault, F; Rodriguez-Lucena, D; Schalk, IJ | 1 |
| Bonchi, C; Frangipani, E; Imperi, F; Minandri, F; Visca, P | 1 |
| Du, R; Jiang, L; Li, LF; Peng, WW; Qu, DL; Wu, TT; Yang, Y; Zhao, JJ; Zhou, ZJ; Zhu, YQ | 1 |
| Ferrer, P; Jacobs-Lorena, M; Sullivan, DJ; Tripathi, AK; Vega-Rodriguez, J | 1 |
| Agis, H; Janjić, K; Kurzmann, C; Moritz, A; Müller, AS; Oberoi, G; Pensch, M | 1 |
2 review(s) available for deferoxamine and thiazoles
| Article | Year |
|---|---|
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
24 other study(ies) available for deferoxamine and thiazoles
| Article | Year |
|---|---|
Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Cells, Cultured; Deferoxamine; Dihydropyridines; Dose-Response Relationship, Drug; Injections, Subcutaneous; Iodine Radioisotopes; Iron; Iron Chelating Agents; Iron Radioisotopes; Liver; Rats; Rats, Wistar; Thiazoles; Time Factors; Transferrin; Weight Gain | 1992 |
Interference with oxidative processes inhibits proliferation of human peripheral blood lymphocytes and murine B-lymphocytes.
Topics: Animals; B-Lymphocytes; Deferoxamine; Dihydropyridines; DNA; Ferricyanides; Humans; In Vitro Techniques; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Oxidation-Reduction; Oxygen; T-Lymphocytes; Thiazoles | 1991 |
A comparative evaluation of iron clearance models.
Topics: Animals; Bile; Chelating Agents; Deferoxamine; Dihydropyridines; Haplorhini; Hydrazines; Iron; Iron Chelating Agents; Male; Rats; Rats, Inbred Strains; Spectrophotometry, Atomic; Thiazoles | 1990 |
The effect of desferrithiocin, an oral iron chelator, on T-cell function.
Topics: Antigens, Surface; Calcium; Cell Division; Cell Membrane; Cells, Cultured; Cytotoxicity, Immunologic; Deferoxamine; Dihydropyridines; Humans; Interleukin-2; Iron; Iron Chelating Agents; Killer Cells, Natural; Lymphocyte Activation; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Thiazoles | 1990 |
Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor.
Topics: Animals; Antioxidants; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Deferoxamine; Dihydropyridines; Free Radicals; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred CBA; Oxygen; Peritoneal Cavity; Thiazoles; Tumor Necrosis Factor-alpha | 1989 |
A non-human primate model for the study of oral iron chelators.
Topics: Administration, Oral; Animals; Cebus; Deferoxamine; Dihydropyridines; Disease Models, Animal; Injections, Intramuscular; Iron; Iron Chelating Agents; Thiazoles | 1989 |
Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
Topics: Animals; Cells, Cultured; Deferoxamine; Dihydropyridines; Iron; Liver; Male; Rats; Rats, Inbred Strains; Thiazoles; Tritium | 1989 |
Iron chelators: in vitro inhibitory effect on the liver stage of rodent and human malaria.
Topics: Animals; Cells, Cultured; Deferoxamine; Dihydropyridines; Humans; Iron Chelating Agents; Liver; Malaria; Microscopy, Electron; Plasmodium falciparum; Plasmodium yoelii; Rats; Thiazoles | 1988 |
Plasmodium falciparum: inhibition in vitro with lactoferrin, desferriferrithiocin, and desferricrocin.
Topics: Animals; Antimicrobial Cationic Peptides; Deferoxamine; Erythrocytes; Humans; Iron Chelating Agents; Lactoferrin; Lactoglobulins; Peptides; Plasmodium falciparum; Pyridines; Thiazoles | 1987 |
An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators.
Topics: Administration, Oral; Animals; Body Weight; Chelating Agents; Deferoxamine; Dihydropyridines; Ferritins; Ferrous Compounds; Injections, Intraperitoneal; Liver; Male; Metallocenes; Organ Size; Organometallic Compounds; Pyridines; Rats; Rats, Inbred Strains; Thiazoles | 1986 |
A rapid colorimetric assay for evaluating Legionella pneumophila growth in macrophages in vitro.
Topics: Animals; Colorimetry; Deferoxamine; Electron Transport; Female; Formazans; Iron; Legionella pneumophila; Macrophages; Mice; Mice, Inbred Strains; Tetrazolium Salts; Thiazoles | 1994 |
A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Topics: Animals; Cebus; Deferoxamine; Dihydropyridines; Feces; Gastrointestinal Diseases; Iron; Kidney Diseases; Male; Rats; Rats, Sprague-Dawley; Siderophores; Thiazoles | 1993 |
The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
Topics: Animals; Cebus; D-Amino-Acid Oxidase; Deferoxamine; Dihydropyridines; Iron; Iron Chelating Agents; Kinetics; Male; Metabolic Clearance Rate; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 1998 |
Differential cellular regulation of the mitochondrial permeability transition in an in vitro model of 1,3-dinitrobenzene-induced encephalopathy.
Topics: Adenosine Triphosphate; Antioxidants; bcl-2-Associated X Protein; bcl-X Protein; Brain Diseases; Calcium; Deferoxamine; Dinitrobenzenes; Electrophysiology; Glioma; Humans; Mitochondria; Neuroblastoma; Oxidation-Reduction; Permeability; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles; Trifluoperazine; Tumor Cells, Cultured; Vitamin E | 2000 |
Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Deferoxamine; Dihydropyridines; Fibroblasts; Hepatocytes; Humans; Iron; Iron Chelating Agents; Male; Mice; Rats; Rats, Wistar; Thiazoles; Tumor Cells, Cultured | 2002 |
Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro.
Topics: Animals; Cell Survival; Cells, Cultured; Cerebral Cortex; Constriction; Cycloheximide; Deferoxamine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Embryo, Mammalian; Erythropoietin; Gene Expression; Glucose; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Ischemic Attack, Transient; Male; Middle Cerebral Artery; Neurons; Nuclear Proteins; Oxygen; Protein Synthesis Inhibitors; Rats; Rats, Wistar; Reperfusion; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors | 2002 |
Aluminum-triggered structural modifications and aggregation of beta-amyloids.
Topics: Aluminum; Amyloid beta-Peptides; Benzothiazoles; Chelating Agents; Circular Dichroism; Deferoxamine; Fluorescent Dyes; Hydrophobic and Hydrophilic Interactions; Liposomes; Peptide Fragments; Protein Conformation; Spectrometry, Fluorescence; Thiazoles | 2005 |
New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Topics: beta-Thalassemia; Carboxylic Acids; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Design; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thiazoles; Transfusion Reaction | 2006 |
Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells.
Topics: Animals; Cells, Cultured; Curcumin; Deferoxamine; Epithelial Cells; Ferric Compounds; Inhibitory Concentration 50; Liver; Oxidative Stress; Quaternary Ammonium Compounds; Rats; Reactive Oxygen Species; Signal Transduction; Tetrazolium Salts; Thiazoles | 2009 |
Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold.
Topics: Antineoplastic Agents; Cell Proliferation; Deferoxamine; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Iron Chelating Agents; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Sulfhydryl Compounds; Thiazoles; Tumor Cells, Cultured | 2010 |
Pyochelin potentiates the inhibitory activity of gallium on Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biological Transport; Citrates; Deferoxamine; Drug Combinations; Drug Synergism; Ferrichrome; Gallium; Oligopeptides; Phenols; Pseudomonas aeruginosa; Siderophores; Sodium Citrate; Thiazoles | 2014 |
Effects of deferoxamine on the repair ability of dental pulp cells in vitro.
Topics: Adolescent; Alkaline Phosphatase; Calcification, Physiologic; Cell Culture Techniques; Cell Differentiation; Cell Hypoxia; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Coloring Agents; Deferoxamine; Dental Pulp; Fluorescent Dyes; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Odontoblasts; Osteocalcin; Regeneration; Siderophores; Tetrazolium Salts; Thiazoles; Young Adult | 2014 |
Antimalarial iron chelator FBS0701 blocks transmission by Plasmodium falciparum gametocyte activation inhibition.
Topics: Animals; Antimalarials; Deferoxamine; Ethyl Ethers; Female; Iron Chelating Agents; Male; Plasmodium falciparum; Thiazoles | 2015 |
Deferoxamine but Not Dimethyloxalylglycine, L-Mimosine, or Cobalt Dichloride Can Interfere with the MTT Assay.
Topics: 3T3 Cells; Amino Acids, Dicarboxylic; Animals; Biocompatible Materials; Cell Line; Cell Survival; Cobalt; Deferoxamine; Dimethyl Sulfoxide; Mice; Mimosine; Tetrazolium Salts; Thiazoles | 2018 |